Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.62 by 41.94 percent. This is a 73.17 percent decrease over earnings of $3.28 per share from the same period last year. The company reported quarterly sales of $78.700 million which beat the analyst consensus estimate of $69.463 million by 13.30 percent. This is a 22.60 percent decrease over sales of $101.685 million the same period last year.